Arrowhead says ARO-MAPT cuts CSF total tau up to 73% in interim Phase 1/2a healthy-volunteer data

• Arrowhead Pharmaceuticals released interim Phase 1/2a data for ARO-MAPT, an investigational RNAi drug targeting tau-related neurodegenerative diseases.
• Results were already presented as interim findings, with additional data scheduled for a company webinar later today.
• Healthy-volunteer dosing produced deep, sustained reductions in a key tau biomarker, supporting the case for infrequent maintenance dosing.
• Safety profile appeared acceptable, with no serious treatment-related events reported in the interim readout.
• Focus now shifts to patient cohorts in early Alzheimer’s disease, with further updates expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014103135) on October 14, 2026, and is solely responsible for the information contained therein.